Active Compounds. Each Dainippon Substance and RiboGene Substance which meets the criteria set forth in Exhibit 1.1 to the satisfaction of the Research Committee shall be designated as an Active Compound and shall be further developed and optimized.
Active Compounds. (a) Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to ImClone during the Research Period. Following the expiration of the Research Period, Active Compounds with respect to which ImClone fails to proceed with Due Diligence shall be deemed to be Inactive Compounds for all purposes hereunder; provided, that any Active Compound which is the subject of claim(s) under a pending Patent shall continue to be treated as an Active Compound during the Exclusivity Period so long as ImClone exercises Due Diligence with respect to any Collaboration Compound.
Active Compounds. Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to Athena for research or application to any Target, within or outside the Collaboration, during the Exclusivity Period and CombiChem shall not knowingly work on or knowingly provide information regarding such Active Compound to any Third Party, except to reject and take any steps necessary to protect Athena's exclusivity hereunder. Following the expiration of the Exclusivity Period Active Compounds for that Target upon which a Patent has not been filed *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. within ninety (90) days following the Research Period shall be deemed to be Inactive Compounds for all purposes hereunder; provided, that any Active Compound which is the subject of claim(s) under a pending Patent shall continue to be treated as Active Compounds until a Patent is issued with respect to one or more of such claims; or until all of such Patent claims have been denied, at which time the compounds which are the subject to those claims shall be Inactive Compounds hereunder.
Active Compounds. At any time prior to the expiration of the Activation Period applicable to a particular Compound, DuPont shall have the right to designate such compound as an Active Compound, as set forth in this Section 3.2 below.
Active Compounds. (a) Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to ImClone during the
Active Compounds. Any Library Compound identified as meeting the ---------------------- definition of an Active Compound through (i) screening of one or more Libraries by Pharmacopeia and/or Schering in the conduct of the Collaboration, or (ii) screening of one or more Libraries by Schering after the term of the Collaboration, shall be an Active Compound. It is understood that no grant of any licenses by Pharmacopeia to Schering, its Affiliates or Sublicensees under Section 4.1 with respect to any Library Compound shall become effective unless and until Pharmacopeia has received notice that such Library Compound is an Active Compound. Pharmacopeia shall be deemed to have received such notice effective upon receipt of a request by Schering to decode a Library Compound. In the event that Schering or its Affiliates or Sublicensees identifies, without decoding by Pharmacopeia pursuant to Section 2.10, a particular Library Compound with activity against a Target, Schering shall give Pharmacopeia notice identifying such Library Compound as an Active Compound, which notice shall be effective upon receipt by Pharmacopeia. Notwithstanding the foregoing, any Active Compound that is subject to a license by Pharmacopeia to a Third Party (as set forth in Section 4.5 or 4.9.5) granted prior to the time the Library Compound is decoded as set forth in Section 2.10 above or, with respect to a Library Compound which is not decoded, the time that Pharmacopeia receives actual notice from Schering as set forth in this Section 2.12, shall not be deemed to be licensed to Schering under Section 4.1.
Active Compounds. Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to Athena for research or application to any Target, within or outside the Collaboration, during the *** and CombiChem shall not knowingly work on or knowingly provide information regarding such Active Compound to any Third Party, except to reject and take any steps necessary to protect Athena's exclusivity hereunder. Following the expiration of the *** *** Active Compounds for that Target *** *** shall be deemed to be Inactive Compounds for all purposes ; provided, that any Active Compound which is *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the commission.
Active Compounds. (a) License to Chiroscience. Array hereby grants to Chiroscience an exclusive, worldwide sublicenseable right and license to make, have made, use, sell, and import, and to authorize others to make, have made, use, sell and import any Active Compounds designated and maintained in accordance with Section 6.3 below under any U.S. or foreign patents owned by Array. The exclusive license granted Chiroscience under this Section 6.2.2(a) with respect to any Compound shall not take effect until and unless Chiroscience has designated that Compound as an Active Compound. The right and license granted Chiroscience under this Section 6.2.2(a) shall become paid-up and irrevocable with respect to a particular Active Compound at such time as Chiroscience has paid all of the Maintenance Fees with respect to such Active Compound as required under Section 6.3.2
Active Compounds. (a) Following the designation of any Collaboration Compound as an Active Compound, such Active Compound shall be exclusively available to Novartis for research and development in the Field, and CombiChem shall not knowingly work on or knowingly provide information regarding such Active Compound to any Third Party, except to reject and take any steps necessary to protect Novartis's exclusivity hereunder. (b) Following the expiration of the Exclusivity Period, Active Compounds upon which a Patent has not been filed within ninety (90) days following the Exclusivity Period shall be deemed to be "Inactive Compounds" for all purposes hereunder; provided, that any Active Compound which is the subject of claim(s) under at least one pending Patent in the Territory shall continue to be treated as Active Compounds until a Patent is issued with respect to one or more of such claims; or until all of such Patent claims have been denied, at which time the compounds which are the subject of those claims shall be Inactive Compounds hereunder.
Active Compounds. At any time during the Research Program that either Party believes that an Active Compound has been identified with regard to any Sanofi Target, it shall notify the JSC, with a written summary of the basis for its view. At its next meeting, or such earlier time as the Parties may agree, the JSC shall either (a) confirm that the identified compound is an Active Compound, or (b) that the identified compound is not an Active Compound, in which case the specific reason for any failure to meet the applicable Active Compound Criteria shall be summarized in writing. The Parties agree that any compound that is an Active Compound shall be Collaboration Compound for all purposes of this Agreement.
